Clinical Trial Update: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Pyrotinib to Docetaxel in adults with advanced non-squamous non-small cell lung cancer harboring a HER2 exon 20 mutation after platinum …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-squamous NSCLC, HER2 Exon 20 Mutation | Phase 3 | Status: COMPLETED